DMTC industry partner Anteo Diagnostics Ltd has notified the ASX of the successful completion of the first milestone in their DMTC project, with initial studies demonstrating high-detection sensitivity.
Anteo has partnered with Planet Innovation, Deakin University and DMTC to further the technology readiness of Planet Innovation’s (Nplex) low cost, high sensitivity point of care diagnostic system using breakthrough reader technology.
Anteo’s contribution and objectives in Milestone 1 were to successfully functionalise nanoparticles requiring integration with Planet Innovation’s reader. Anteo has successfully established, optimised and verified a model lateral flow system for the nominated target assay using Mix&Go.
Work on the next milestone is already underway and is scheduled to be completed by next quarter.
The DMTC Medical Countermeasures (MCM) program recognises the increasingly important need to create, in Australia, an integrated multidisciplinary network focused on MCM product development.
Anteo’s statement is available here.Posted by Harry Baxter Tagged: DMTC, MCM, research